KeyBanc Capital Markets analyst Matthew Gillmor increased the price target on Encompass Health Corp (NYSE:EHC) to $120 from $117, while maintaining an Overweight rating on the company's shares. The ...

Cliffs, Nucor, U.S. Steel, and Steel Dynamics rise after President Donald Trump says he will impose 25% levies on all steel ...

Is IDEXX Laboratories a good investment? Analyzing its consistent growth, innovative products, and international expansion ...

Benchmark analysts upgraded shares of the e-commerce platform to Buy from Hold and established a price target of $150.

Fed Chair Jerome Powell’s testimony before Congress will remain on TSX investors’ radar today as investors await more details ...

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

Donald Trump's new 25% tariffs on US metal imports will impact countries like Canada, Brazil, and Mexico the most.

D.A. Davidson analyst Linda Bolton Weiser maintained a Buy rating on Prestige Consumer Healthcare (PBH – Research Report) today and set a price ...

Drugmaker Incyte Corp reported fourth-quarter revenue above Wall Street estimates on Monday, boosted by strong demand for its key blood-cancer drug Jakafi and skin-disorder treatment Opzelura.

Elliott Investment Management said a breakup of Honeywell could push the stock up 51% to 75% over the next two years. But ...

Shares of Fidson Healthcare Plc rose by 24% in the first week of February 2025, with a trading volume of 8.8 million shares, securing a spot on the NGX’s advancers list for the week. The stock closed ...

Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has ...